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Background: The associations between the polymorphisms in Cytotoxic T lymphocyte-associated molecule-4
(CTLA-4) gene and Graves’ disease (GD) have been extensively investigated in Chinese population. However, the
results were inconsistent. The objective of this study is to investigate the associations between the polymorphisms
in CTLA-4 gene and the risk of GD by meta-analysis.
Methods: We searched Pubmed database, Medline (Ovid) database, CNKI database and Wanfang database,
covering all studies until August 11, 2012. Statistical analysis was performed by using the Revman4.2 software and
the Stata10.0 software.
Results: A total of 28 case–control studies concerning the most widely studied three polymorphisms [+49A/G
(rs231775), -318C/T(rs5742909) and CT60(rs3087243)] for Chinese population in 21 publications were included. The
results suggested that the G allele carriers (GG+GA) might have an increased risk of GD when compared with the
AA homozygote carriers for the +49A/G polymorphism (GG+GA vs. AA: OR = 2.57, 95%CI = 1.87-3.52). However, as
to the -318C/T polymorphism and CT60 polymorphism, the results indicated that the variant allele carriers might
have decreased risks of GD when compared with the homozygote carriers (−318C/T: TT+TC vs. CC: OR = 0.78, 95%
CI = 0.62-0.97; CT60: AA+AG vs. GG: OR = 0.64, 95%CI = 0.52-0.78).
Conclusions: The current meta-analysis indicated that the polymorphisms in the CLTA-4 gene might be risk
factors for GD in the Chinese population. In future, more large-scale case–control studies are needed to validate
these results.
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Graves’ disease (GD) is a complex autoimmune thyroid
disease, which is caused by excessive production of thy-
roid hormone and characterized by an enlarged thyroid
gland, protrusion of the eyeballs, a rapid heartbeat and
nervous excitability [1]. It is reported that GD occurs in
about 1.2% in Western population and 0.25–1.09% in
Chinese population [2]. It is widely accepted that GD is
caused by complex interactions between many genetic* Correspondence: liangdu123@yahoo.cn; michael.huangjin@gmail.com
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reproduction in any medium, provided the orfactors and environmental factors. Numerous studies
have been published focusing on the topic of genetic
factors of GD risk in the Chinese population. Many
genes involved in the inception and evolution of GD
have been identified as GD candidate genes, such as
ADRB2 [3], TSHR [4], CTLA-4 [5] and IL-13 gene [6].
And among them, the CTLA-4 gene is one of the most
extensively studied.
Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4)
is a T cell surface molecule [7]. It is a negative regulator of
T cell activation and plays an important role in the patho-
genesis of GD. The CTLA-4 gene is localized on chromo-
some 2q33. Many polymorphisms have been identified in
the CTLA-4 gene. It is reported that the polymorphisms inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tein, and might play important roles in the pathogenesis
of GD [8]. Up to now, many studies have been performed
to investigate the associations between the polymorphisms
in the CTLA-4 gene and the risk of GD. Among them,
the +49A/G, -318C/T and CT60 polymorphisms were the
most widely studied. To this day, the associations between
polymorphisms of the CTLA-4 gene and the risk of GD
have been widely investigated in the Chinese population.
However, the results were inconsistent, and the associa-
tions were not yet formally evaluated. In order to derive a
more precise conclusion, we performed a meta-analysis to
assess the associations between the polymorphisms in the
CTLA-4 gene and the risk of GD in the Chinese popula-
tion. To our knowledge, this is the first comprehensive
genetic meta-analysis performed in the Chinese popula-
tion for Graves’ disease.
Methods
Study identification and selection
A literature search in Pubmed database, Medline (Ovid)
database, CNKI database and Wanfang database was
carried out to identify studies investigating the associ-
ation between the Graves’ disease risk and the CTLA-4
polymorphisms on Aug 11th, 2012. The search terms
were as follows: Graves’ disease or GD in combination
with polymorphism or variant or mutation and in com-
bination with CTLA-4 or Cytotoxic T lymphocyte-
associated molecule-4. All languages were included.
The inclusion criteria were: (a) studies evaluating the
association between the (+49A/G, -318C/T and CT60)
polymorphisms in the CTLA-4 gene and Graves’ disease
risk in the Chinese population, (b) the design should be
a case–control design, (c) sufficient data (genotype dis-
tributions of cases and controls) available to calculate
an odds ratio (OR) with its 95%CI (confidence interval),
(d) genotype distributions in control group should be
consistent with Hardy-Weinberg equilibrium (HWE).
Studies were excluded if one of the following existed:
(a) the studied populations were based on family or sib-
ling pairs, (b) genotype frequencies or numbers were
not presented in the original studies, (c) reviews and
abstracts. If more than one study was published by
the same authors using the same case series or overlap-
ping case series, studies with the largest size of samples
were included.
Data extraction
Two investigators independently extracted the data
and reached a consensus on all items. The following
items were extracted from each study if available: first
author’s name, publication year, province of origin,
age of cases, genotype number in cases and controls
and genotyping method.Statistical analysis
The strength of associations between the polymor-
phisms in the CTLA-4 gene and Graves’ disease risk
was assessed by odds ratios (OR) with the correspond-
ing 95% confidence intervals (CI). The genetic models
evaluated for the pooled OR of the polymorphisms
were dominant models (GG+GA vs. AA for the +49A/G,
TT+TC vs. CC for the -318C/T, and AA+AG vs. GG for
the CT60). OR was analyzed by a fixed-effects model
(the Mantel-Haenszel method) or a random-effects
model (the DerSimonian and Laird method) according to
the heterogeneity. Heterogeneity was assessed by a X2
based Q statistic and was considered statistically signifi-
cant at p-value <0.10. When the P value was more than
0.10, the pooled OR was calculated by the fixed-effects
model, otherwise, a random-effects model was used. The
significance of the pooled OR was determined by the Z-test
and p-value less than 0.05 was considered as statistically
significant. Sensitivity analysis was conducted by sequential
excluding a single study each time in an attempt to identify
the potential influence of the individual data set to the
pooled ORs. In addition, the possible publication bias was
investigated with the Begg’s funnel plot. Funnel plot asym-
metry was assessed by Egger’s linear regression test [9]. For
each polymorphism, other genetic models were also used
to assess the association with the risk of Graves’ disease
(for the +49A/G polymorphism: GG vs. AA+GA, GG vs.
AA, GA vs. AA, G vs. A; for the -318C/T polymorphism:
TT vs. CC+TC, TT vs. CC, TC vs. CC, T vs. C; for the
CT60 polymorphism: AA vs. AG+GG, AA vs. GG, AG vs.
GG, A vs. G). HWE was tested by Person’s X2 test. Statis-
tical analysis was performed using Revman4.2 software and
Stata10.0 software.
Results
Studies selection and characteristics
The selection process of studies was as follows. Briefly, a
total of 429 results were identified after an initial search
from the Pubmed, Medline (Ovid), CNKI and Wanfang
databases. After reading the titles and abstracts, 302 re-
sults were excluded for being irrelevant to CTLA-4 poly-
morphisms and Graves’ disease risk, abstracts, reviews
or duplications of search results. After reading full-texts
of the remaining 127 studies, 68 studies were excluded
for not relevant to the GD risk in the Chinese population,
and 9 studies were excluded for not relevant to the inves-
tigated polymorphisms (+49A/G, -318C/T and CT60).
Thus, 50 studies were left for data extraction. And then,
a total of 54 case–control studies were extracted for
these three polymorphisms. Among 54 case–control
studies, genotype numbers for control group in 7 stud-
ies were not consistent with HWE, data in 19 studies
were overlapped. So these 27 case–control studies were
excluded. Finally, a total of 28 case–control studies in 21
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Summary of the properties of the studies are listed in
Table 1. Overall, there were 17 case-controls studies for
the +49A/G polymorphism [2,5,11-13,15,17-25,27,28], 7
case–control studies for the -318C/T polymorphism
[2,10-12,14,26,28] and 4 case–control studies for the
CT60 polymorphism [2,10,16,18]. The genotype distribu-
tions for these polymorphisms are listed in Table 2.
Quantitative synthesis
The +49A/G polymorphism
A total of 4009 cases and 3651 controls from 17 case–con-
trol studies were included for data synthesis. As is shown
in Figure 1, we analyzed the heterogeneity of GG+GA vs.
AA for all 17 studies and the value of X2 was 47.22 with 16
degrees of freedom and p-value < 0.00001 in a random-
effects model. Additionally, I-square value is another index
of the test of heterogeneity. In Figure 1, the I-square was
66.1%, suggesting a moderate of heterogeneity. Thus, we
chose the random-effects model to synthesize the data.
Overall, OR was 2.57 (95%CI = 1.87-3.52) and the test for
overall effect Z value was 5.83 (p-value < 0.00001). The re-
sults suggested that the G allele carriers might have an in-
creased risk of Graves’ disease compared with those





Chong, K K [10] 2008 Hong Kong <
Du, Y T [11] 2005 Tianjin
Guo, Z Q [12] 2010 Shandong 44.17
Han, S Z [2] 2006 Chongqing
Jiang, B R [13] 2005 Shandong 43.8
Kang, Y Z [14] 2010 Ningxia 43.7
Shen, F X [15] 2005 Zhejiang 36.0
Tsai, S T [16] 2008 Taiwan 10.2
Wang, L [17] 2001 Shandong 40
Wang, P W [18] 2007 Taiwan 39
Wang, Q H [19] 2003 Zhejiang 45.7
Wang, S Q [20] 2010 Shandong 41.5
Weng, Y C [21] 2005 Taiwan 34.0
Yang, J [22] 2012 Xi’an 34.14
Yao, B [23] 2005 Guangdong 36.6
Yu, Q L [24] 2006 Guangdong 45
Yu, Z Y [25] 2008 Xi’an 36.7
Zhang, H [26] 2010 Shandong
Zhang, J L [27] 2008 Shandong 37.8
Zhang, Q [28] 2006 Zhejiang
Zhao, S X [5] 2010 Shandong, Suzhou, Guangdong, Fujianresults were obtained after sequential excluding each case–
control study for the GG+GA vs. AA comparative,
suggesting the stability of our meta-analysis. Significant
publication bias was detected in the funnel plot (figure not
shown), and in the Egger’s test, the result was: t = 2.82,
p-value = 0.013, which also indicated considerable publica-
tion bias. Summary of the results of other genetic compari-
sons are listed in Table 3.
The -318C/T polymorphism
A total of 999 cases and 702 controls from 7 case–
control studies were included for data synthesis. As is
shown in Figure 2, we analyzed the heterogeneity of
TT+TC vs. CC for all 7 studies and the value of X2 was
2.56 with 6 degrees of freedom and p-value = −0.86 in a
fixed-effects model. Additionally, I-square value is an-
other index of the test of heterogeneity. In Figure 2, the
I-square was 0%, suggesting an absent of heterogeneity.
Thus, we chose the fixed-effects model to synthesize the
data. Overall, OR was 0.78 (95%CI = 0.62-0.97) and the
test for overall effect Z value was 2.18 (p-value = 0.03).
The results suggested that the T allele carriers might have
a decreased risk of Graves’ disease compared with those
individuals with the CC homozygote. Statistically similar
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Table 2 Distribution of CTLA-4 genotype among patients with Graves’ disease and controls included in the
meta-analysis
Polymorphism Author Case Control Case Control HWE
+49A/G polymorphism AA AG GG AA AG GG A G A G
Du, Y T [11] 1 27 68 7 26 27 29 163 40 80 Yes
Guo, Z Q [12] 24 52 26 41 47 12 100 104 129 71 Yes
Han, S Z [2] 33 95 135 32 89 75 161 365 153 239 Yes
Jiang, B R [13] 10 44 44 33 46 16 64 132 112 78 Yes
Shen, F X [15] 5 34 68 4 30 23 44 170 38 76 Yes
Wang, L [17] 3 47 37 32 42 10 53 121 106 62 Yes
Wang, P W [18] 15 69 124 18 77 97 99 317 113 271 Yes
Wang, Q H [19] 21 24 19 12 15 1 66 62 39 17 Yes
Weng, Y C [21] 8 53 46 15 58 28 69 145 88 114 Yes
Wang, S Q [20] 5 47 38 24 52 14 57 123 100 80 Yes
Yang, J [22] 12 139 152 29 97 89 163 443 155 275 Yes
Yao, B [23] 9 53 58 11 57 55 71 169 79 167 Yes
Yu, Q L [24] 13 36 51 28 46 26 62 138 102 98 Yes
Yu, Z Y [25] 13 45 67 20 60 46 71 179 100 152 Yes
Zhang, J L [27] 16 100 70 32 43 25 132 240 107 93 Yes
Zhang, Q [28] 2 29 58 7 26 27 33 145 40 80 Yes
Zhao, S X [5] 104 730 1030 156 823 945 938 2790 1135 2713 Yes
−318C/T polymorphism CC CT TT CC CT TT C T C T
Chong, K K [10] 147 28 2 122 29 0 322 32 273 29 Yes
Du, Y T [11] 80 13 3 46 12 2 173 19 104 16 Yes
Guo, Z Q [12] 84 18 0 76 23 1 186 18 175 25 Yes
Kang, Y Z [14] 52 8 1 48 11 1 112 10 107 13 Yes
Zhang, H [26] 175 35 1 69 16 0 385 37 154 16 Yes
Han, S Z [2] 159 98 2 103 85 2 416 26 291 101 Yes
Zhang, Q [28] 65 22 6 46 12 8 152 110 104 16 Yes
CT60 polymorphism GG AG AA GG AG AA G A G A
Chong, K K [10] 125 48 4 88 51 12 298 56 227 75 Yes
Han, S Z [2] 184 71 8 123 60 13 439 87 306 86 Yes
Tsai, S T [16] 136 48 5 372 216 32 320 58 960 280 Yes
Wang, P W [18] 138 46 5 125 58 9 322 56 308 76 Yes
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suggesting the stability of our meta-analysis. No publica-
tion bias was detected with either the funnel plot (figure
not shown) or Egger’s test (t = 0.09, p-value = 0.929).
Summary of the results of other genetic comparisons are
listed in Table 3.
The CT60 polymorphism
A total of 818 cases and 1159 controls from 4 case–
control studies were included for data synthesis. As is
shown in Figure 3, we analyzed the heterogeneity of
AA+AG vs. GG for all 4 studies and the value of X2
was 0.91 with 3 degrees of freedom and p-value = 0.82in a fixed-effects model. Additionally, I-square value is
another index of the test of heterogeneity. In Figure 3, the
I-square was 0%, suggesting an absent of heterogeneity.
Thus, we chose the fixed-effects model to synthesize the
data. Overall, OR was 0.64 (95%CI = 0.52-0.78) and the test
for overall effect Z value was 4.34 (p-value = 0.001). The re-
sults suggested that the A allele carriers might have a de-
creased risk of Graves’ disease compared with those
individuals with the GG homozygote. Statistically similar
results were obtained after sequential excluding each case–
control study for the AA+AG vs. GG comparative,
suggesting the stability of our meta-analysis. No publica-
tion bias was detected with either the funnel plot (figure
Figure 1 Meta-analysis with a random-effects model for the association between GD risk and the CTLA-4 +49A/G polymorphism
(GG+GA vs. AA).
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mary of the results of other genetic comparisons are listed
in Table 3.
Discussion
Graves' disease (GD) is a thyroid-specific autoimmune
disease affecting 0.25–1.09% of the Chinese population
[2]. To this day, the mechanisms of GD have been widelyTable 3 Summary of different comparative results
Polymorphism Genetic model Participants OR (95%CI)
+49A/G GG+GA vs. AA 7660 2.57(1.87,3.52)
GG vs. GA+AA 7660 2.11(1.70,2.63)
GG vs. AA 4402 3.87(2.59,5.80)
GA vs. AA 4053 1.96(1.44,2.67)
G vs. A 15320 1.88(1.58,2.23)
−318C/T TT+TC vs. CC 1701 0.78(0.62,0.97)
TT vs. TC+CC 1701 0.76(0.37,1.53)
TT vs. CC 1291 0.70(0.35,1.43)
TC vs. CC 1672 0.78(0.62,0.98)
T vs. C 3402 0.80(0.66,0.98)
CT60 G/A AA + AG vs. GG 1977 0.64(0.52,0.78)
AA vs. AG + GG 1977 0.43(0.26,0.72)
AA vs. GG 1379 0.39(0.23,0.65)
AG vs. GG 1889 0.69(0.55,0.85)
A vs. G 3954 0.65(0.54,0.77)studied from the environmental factors to the genetic
factors [29]. However, the results are inconsistent and
the exact mechanisms are still unrevealed. Among gen-
etic risk factors, the cytotoxic T lymphocyte associated-4
(CTLA-4) gene is one of the widely investigated. CTLA-4
gene, which encodes a vital negative regulatory molecule of
the immune system [30], has been demonstrated as candi-
date gene of GD [31,32]. To date, three polymorphismsZ p-value I2, % PHet Effect model
5.83 < 0.00001 66.1 < 0.0001 Random
6.69 < 0.00001 70.3 < 0.00001 Random
6.57 < 0.00001 74.3 < 0.00001 Random
4.25 < 0.00001 60.8 0.0006 Random
7.18 < 0.00001 76.8 < 0.00001 Random
2.18 0.03 0 0.86 Fixed
0.78 0.44 0 0.92 Fixed
0.97 0.33 0 0.90 Fixed
2.11 0.03 0 0.86 Fixed
2.12 0.03 0 0.88 Fixed
4.34 < 0.0001 0 0.82 Fixed
3.22 0.001 0 0.82 Fixed
3.62 0.0003 0 0.81 Fixed
3.52 0.0004 0 0.82 Fixed
4.9 < 0.00001 0 0.81 Fixed
Figure 2 Meta-analysis with a random-effects model for the association between GD risk and the CTLA-4 -318C/T polymorphism
(TT+TC vs. CC).
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risk factors in the Chinese population. However, the results
were inconsistent. Therefore, we performed a comprehen-
sive meta-analysis to assess the association and to get more
conclusive results.
This meta-analysis, including a total of 28 case–control
studies in 21 publications, investigated three most widely
studied polymorphisms in the CTLA-4 gene. We found
that the +49A/G polymorphism was associated with an in-
creased risk of GD in the Chinese population, and the G al-
lele carriers might have a higher risk of disease than the
AA homozygote carriers. The results suggested a signifi-
cant association between this polymorphism in the Chinese
population, which is consistent with some other popula-
tions, such as the UK population [33] and the Iranian
population [34]. Our results indicated that the increase in
the risk is more evident in the Chinese population than in
other populations, suggesting possible roles of ethnic dif-
ferences in genetic backgrounds and the environment. In
addition, the +49A/G polymorphism is located in exon 1,Figure 3 Meta-analysis with a random-effects model for the associati
(AA+AG vs. GG).and results in a threonine-to-alanine conversion at codon
17 in the peptide leader sequence of the CTLA-4 protein.
It reported that this polymorphism was associated with
lower mRNA levels of the soluble alternative splice form of
CTLA-4 [35]. Thus, our results could be partly explained
that the variant carriers might have lower mRNA levels of
the protein of the CTLA-4, and then have increased risk of
the disease. In future, more studies should be performed in
the Chinese population to validate these results.
A total of 999 cases and 702 controls from 7 case–
control studies were included for the -318C/T poly-
morphism. The results suggested that the T allele carriers
might be associated with a decreased risk of GD com-
pared with CC homozygote carriers. As for the CT60
polymorphism, 818 cases and 1159 controls from 4
case–control studies were included, and the results also
indicated a decrease in the risk of GD. Considering the
included case–control studies for both polymorphisms
were relatively small, larger number of relevant studies
are needed in future to validate these results.on between GD risk and the CTLA-4 CT60 polymorphism
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cusing on the genetic risk factors of the GD among the
Chinese population. For instance, Chu reported that a
non-synonymous single-nucleotide polymorphism rs40401
(P27S) of the interleukin 3 (IL3) gene was associated with
increased risk of GD [36]; Guo found the rs568408 poly-
morphism in the interleukin-12 (IL-12) gene was also as-
sociated with increased risk of GD [37]. In addition,
polymorphisms in the ADRB2 gene [3], interleukin-10
(IL-10) gene [38], TNF-α gene [39] were also found
to be associated with GD in Chinese population.
These genes were all suggested as the candidate
genes for GD in Chinese population. In future, the
associations between these polymorphisms and the
GD risk in Chinese population are needed to be vali-
dated by more case–control studies.
In the present meta-analysis, sensitivity analysis was
performed and stability of the results was guaranteed.
Publication bias was assessed by Begg’s funnel plot and
Egger’s test [40]. No significant publication bias was
found for the -318C/T and the CT60 polymorphism ana-
lysis, suggesting the results of these two polymorphisms
were more reliable. However, we found significant publi-
cation bias for the +49A/G polymorphism. The reason
might be that some reports were not published, espe-
cially for those with negative results. The results might
affect the strength of the association, thus, large scale
case–control studies are needed to assess the association
between the +49A/G polymorphism and GD risk.
We have to mention the heterogeneity. We found sig-
nificant heterogeneity for the +49A/G polymorphism.
Since all participants were Chinese, the genetic back-
ground might not be taken as a factor for the heterogen-
eity for +49A/G polymorphism. However, some other
factors, such as gender, age and location might affect the
heterogeneity. In addition, we found no heterogeneity for
the -318C/T and the CT60 polymorphisms, which sug-
gested that the association for these two polymorphisms
are more reliable than the +49A/G polymorphism.
It is reported that GD occurs more frequently but less se-
vere in women than in men. In China, the different condi-
tion of disease in men and women might be similar to the
situation of the world. In our study, the data was not ana-
lyzed by gender because of the lack of original information
for these populations. In future, such subgroup studies are
also needed to be carried out. Moreover, the cases and con-
trols in this meta-analysis were mostly based on Han na-
tionality, but not in the minorities. In order to get
comprehensive results of the Chinese population, studies
based on the minorities are also needed.
There are several limitations in this meta-analysis.
First, the quantity of enrolled published studies was not
very ideal, especially for the -318C/T and CT60 poly-
morphism. This might cause some potential publicationbias, although the results of the above mentioned bias tests
was not significant for these two polymorphisms. Second,
data were not stratified into subgroups according to some
other factors such as age, gender, location and ethnicity
(Han or others), due to the lack of information in the ori-
ginal studies. Third, the interactions between genetic fac-
tors and environmental factors were not discussed for
these three polymorphisms. Fourth, the current meta-
analysis only investigated the three most widely studied
polymorphisms, and some other polymorphisms with
fewer reports were not included. And in future, if there
were more case–control studies, new meta-analysis should
be conducted. Despite of these limitations, we have mini-
mized the bias through the whole process based on means
in study identification, data selection and statistical analysis
as well as in the control of publication bias and sensitivity,
and got a more reliable result.
Conclusions
To our knowledge, this is the first comprehensive gen-
etic meta-analysis performed in Chinese population for
Graves’ disease and CTLA-4 gene. We found that three
polymorphisms (+49A/G, -318C/T and CT60) in the
CTLA-4 gene were associated with the risk of GD. Our
results supported the classic view that GD is associated
with heredity and revealed that genes in the pathogen-
esis are important for GD. These results may have impli-
cations for further medicine researches about GD for
the Chinese population. In future, more large-scale
case–control studies are needed to validate our results.
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